Different Presentations and Different Treatment Options in Blastic Plasmacytoid Dendritic Cell Neoplasms: A Case Series

Esra Cengiz; Muruvvet Seda Aydin; Ahmet K Gunes; Funda Ceran; Simten Dagdas; Gulsum Ozet

doi:10.18502/ijhoscr.v19i1.17829

Esra Cengiz Şanlıurfa Mehmet Akif İnan Education and Training Hospital, Şanlıurfa, Turkiye
Muruvvet Seda Aydin Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye
Ahmet K Gunes Ankara Etlik City Hospital, Department of Hematology, Ankara, Turkiye
Funda Ceran Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye
Simten Dagdas Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye
Gulsum Ozet Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye

DOI: https://doi.org/10.18502/ijhoscr.v19i1.17829

Keywords: Bendamustine; Blastic plasmacytoid dendritic cell neoplasm; Chemotherapy; Minimal residual disease; Stem cell transplantation

Abstract

Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms¹. Therapies include chemotherapy or immunotherapy^2-4though stem cell transplantation (SCT) is the best consolidative approach in eligible patients⁵. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN.